GET DAILY SIGNALSWhy Is MDxHealth (MDXH) Stock Down -14.52% Today?
Key Takeaways
- Shares of MDXH were down about 14.5% in Monday's session, trading near $0.18 after closing Friday at $0.2066.
- The primary catalyst was a BTIG downgrade to Neutral from Buy, with the analyst citing a weak preliminary third-quarter revenue print and a suspended full-year outlook.
- The move extends a brutal Friday selloff, when MDXH plunged roughly 66% following the company's guidance withdrawal.
- Management blamed unexpected sales-force turnover, triggered after the company wound down its Resolve mdx urinary-tract test earlier this year.
- Traders are now watching the company's November 12 earnings call and its Nasdaq listing-compliance status.
Opening Summary
MDXH, the Nasdaq-listed shares of MDxHealth SA — a Belgian-headquartered precision diagnostics company focused on urology and prostate-cancer testing — extended a steep multi-day decline on Monday. As of mid-session, the stock traded near $0.1766, down about 14.5% from Friday's closing price of $0.2066. The selloff was driven by a fresh analyst downgrade and continued fallout from the company's disclosure last week that third-quarter revenue missed expectations and that it was suspending its full-year 2026 guidance.
Analyst Downgrade Deepens the Selloff
The immediate catalyst for Monday's drop was BTIG's decision to cut MDXH to Neutral from Buy, removing its price target. The analyst pointed to the company's pre-announced third-quarter revenue and volume miss and, notably, its decision to suspend 2026 revenue guidance. The note signaled that confidence in the company's near-term growth trajectory has deteriorated and that rebuilding that confidence may take time.
The downgrade follows similar actions late last week, when both Craig-Hallum and Lake Street moved MDXH to Hold-equivalent ratings. Lake Street slashed its price target to $0.50 from $3.00, underscoring how quickly the Street's view has shifted.
Guidance Suspension and a Q3 Revenue Miss
The root of the decline lies in the company's October 15 announcement that preliminary third-quarter 2026 revenue from continuing operations would be approximately $22.7 million — flat versus the prior-year period and well below the roughly $28.8 million consensus estimate. Management simultaneously suspended its full-year 2026 revenue guidance of $110–115 million, a move that removed the earnings framework investors had relied on to value the company.
The quarter showed a meaningful divergence between product lines. Tissue-based test volume for Confirm mdx and GPS mdx fell 11% year over year to 11,232 tests, while liquid-based Exo mdx volume more than doubled to 11,792 tests. The decline in the core tissue franchise — which represents the bulk of revenue — overshadowed the liquid-biopsy growth.
Sales-Force Turnover Disrupts Execution
Chief Executive Michael K. McGarrity attributed the shortfall to unexpected turnover within the company's sales force, which he said was "catalyzed by aggressive targeting from recruiters" following the decision to discontinue the Resolve mdx urinary-tract business earlier in 2026. The attrition disrupted the forecasting process that had underpinned the company's guidance accuracy in recent years and interrupted the recovery the company reported in the second quarter. While management argued that underlying clinical demand and long-term market opportunity remain intact, investors have been unwilling to grant the benefit of the doubt.
Market Context and Trading Activity
The current decline compounds Friday's collapse, when shares closed down roughly 66% at $0.2066. Friday's session was marked by extraordinary volume — more than 11.6 million shares changed hands, compared with the roughly 120,000 to 280,000 shares traded in the preceding sessions. The move was company-specific rather than a reflection of the broader healthcare or diagnostics sector, which did not experience a comparable drawdown. With the stock now trading near all-time lows and below the $1.00 Nasdaq minimum-bid threshold, technical support levels have largely given way, leaving sentiment-driven trading as the dominant force.
What Comes Next for MDXH
Investors will look to the company's November 12 third-quarter earnings report and conference call, where management has pledged to detail its corrective actions and progress in stabilizing its sales territories. Key areas of focus include whether tissue-based test volume stabilizes, whether the company can credibly reintroduce guidance, and how its roughly $31.7 million cash position at September 30 supports operations. The stock also faces a Nasdaq listing-compliance clock after receiving a minimum-bid notice earlier this year, adding to the uncertainty. Risks include continued sales-force attrition, covenant and liquidity pressures, and the possibility of further analyst downgrades.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page curates the strongest-performing AI trading bots from a universe of hundreds of bots covering thousands of tickers. Each bot differs by strategy, timeframe, performance metrics, and the symbols it trades, and only those excelling under current market conditions are featured. Explore the Trending AI Robots page to see which strategies are currently outperforming.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
MDXH in -67.30% downward trend, falling for three consecutive days on October 16, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MDXH declined for three days, in 152 of 178 cases, the price declined further within the following month. The odds of a continued downward trend are 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 26 of 34 cases where MDXH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDXH as a result. In 40 of 50 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for MDXH turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 31 similar instances when the indicator turned negative. In 23 of the 31 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
MDXH moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MDXH crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for MDXH entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for MDXH's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +11.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDXH advanced for three days, in 95 of 122 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
MDXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.641) is normal, around the industry mean (63.879). P/E Ratio (0.000) is within average values for comparable stocks, (1.769). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. MDXH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDXH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the scope of Interactive Brokers' recent expansion of after-hours trading options for U.S. stocks and ETFs?
How did the better-than-expected bank earnings affect the stocks in the Dow Jones today?
Revolutionizing Data Processing: AI-Powered Pattern Recognition Systems
AI Trading Bots: Top 10 Day Traders, Signals Only, on November 24, 2024
AI Trading Bots: Top 10 Swing Traders, Virtual Accounts, on December 27, 2024
General Information
Industry MedicalSpecialties
Advertisement